Reprogramming RNA To Transform Patients’ Lives

Disease interrupted

RNA processing is the pathway occurring after DNA transcription and controls the production of mature mRNA and protein expression. At Remix Therapeutics we are developing therapies to co-opt and reprogram this pathway to treat undruggable disease. Our proprietary REMaster technology platform enables the identification of compounds that alter RNA processing and correct dysregulation or eliminate deleterious genes altogether.


Remixers are driven to address unmet medical need by advancing our small molecule RNA reprogramming technology to generate novel therapeutics for patients and their caregivers.